- Morning Sickness
- Drugs in Pregnancy
- Alcohol, Nicotine, Substance Use
- Folic Acid
- Breastfeeding & Drugs
- Cancer in Pregnancy
- HIV and HIV Treatment
- Conditions in Pregnancy
- Infectious Diseases in Pregnancy
- Occupational & Environmental Exposures
- Pharmacokinetics/ Drug Metabolism
- The ReproPsych Group
- CAS Newsletter
1-877-327-4636 Alcohol and Substance
1-800-436-8477 Morning Sickness
1-888-246-5840 HIV and HIV Treatment
1-877-439-2744 Motherisk Helpline
416-813-6780 Motherisk Helpline
Pregnancy & Breastfeeding Resources
2013 FACE meeting
Fetal Alcohol Canadian Expertise (FACE) Satellite Meeting .
- Read more in our News Archive
Current Studies at Motherisk
Study seeks women between 4 and 12 weeks in their pregnancy with morning sickness (NVP)
Pregnancy in Women with Multiple Sclerosis
Environmental Exposures and Children's Health
Alcohol Use during Pregnancy
Control of Hypertension in Pregnancy Study
Folic Acid Before and During Pregnancy
Lamisil in Pregnancy
Meridia in Pregnancy
Autoimmune Diseases in Pregnancy Project
Cancer in Pregnancy: Melphalan
Melphalan is an alkylating agent used as an antineoplastic agent. Please see review on mechlorethamine for more information on a related agent.
|Animal studies *||We did not find any reproductive animal study on melphalan. Melphalan, as well as chlorambucil induces specific locus and dominant lethal mutations in germ cells of male mice 1.|
|Human studies||Case report||1st trimester||One report of miscarriage in one woman who was treated with melphalan only during the first trimester of pregnancy 2.|
|Case series||pre-pregnancy||In a study following 436 survivors treated with chemoterapy for gestational trophoblastic tumors, 15 received melphalan as part of their treatment. Three of these women had at least one live birth and 12 reported supression of ovarian function resulting in amenorrhea 3.|
|Epidemiological studies||No epidemiological studies of congenital anomalies in infants born to women who were treated with melphalan during pregnancy have been reported|
- Generoso et al: Dominat lethal and heritable translocation tests with chlorambucil and melphalan in male mice. MutatRes 345: 167-80, 1995.
- Zemlickis, D., et al. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 152: 573-576,1992.
- Rustin GJS, Booth M, Dent J et al:. Pregnancy after cytotoxic chemotherapy for gestational trophoblastic tumors. Br Med J 288:103-6,1984.